Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Lantern Pharma (LTRN – Research Report), LifeMD (LFMD – Research Report) and Calliditas Therapeutics (CALT – Research Report).
Lantern Pharma (LTRN)
In a report released today, Emily Bodnar from H.C. Wainwright assigned a Hold rating to Lantern Pharma. The company’s shares closed last Wednesday at $2.80, close to its 52-week low of $2.38.
According to TipRanks.com, Bodnar is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
The the analyst consensus on Lantern Pharma is currently a Hold rating.
See Insiders’ Hot Stocks on TipRanks >>
LifeMD (LFMD)
In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on LifeMD, with a price target of $10.00. The company’s shares closed last Wednesday at $7.16, close to its 52-week high of $7.77.
According to TipRanks.com, Chen has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
Currently, the analyst consensus on LifeMD is a Strong Buy with an average price target of $8.75.
Calliditas Therapeutics (CALT)
H.C. Wainwright analyst Arthur He CFA maintained a Buy rating on Calliditas Therapeutics today and set a price target of $50.00. The company’s shares closed last Wednesday at $16.70.
According to TipRanks.com, CFA is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
Currently, the analyst consensus on Calliditas Therapeutics is a Strong Buy with an average price target of $31.67, implying an 88.8% upside from current levels. In a report issued on November 7, LifeSci Capital also maintained a Buy rating on the stock with a $44.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on LTRN:
